Previous 10 | Next 10 |
2024-02-07 13:23:24 ET More on S&P 500 Index: A Technical View Of Potential Downside For The Market Sterling Moves Back Into Previous Trading Range, But Will It Hold? The Warning Signs In The Stock Market Are Clear And Present (Technical Analysis) Histori...
2024-02-07 09:45:00 ET Dividend stocks are a great source of passive income. For those who opt to reinvest their dividends, the move can substantially boost returns over the long run. And while top income stocks often attract plenty of attention from eager investors who bid up their share p...
2024-02-06 23:00:25 ET Image source: The Motley Fool. Gilead Sciences (NASDAQ: GILD) Q4 2023 Earnings Call Feb 06, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: Gilead Sciences (GILD) Q4 2023 Earnings Call Transcript
2024-02-06 20:24:07 ET Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript February 06, 2024, 05:00 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O’Day - Chairman and Chief Executive Officer Johanna Mercier -...
2024-02-06 17:51:49 ET More on Gilead Sciences Gilead Sciences: The Sky Is Not Falling Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Gilead Sciences Non-GAAP EPS of $1....
2024-02-06 16:43:45 ET More on Gilead Sciences Gilead Sciences: The Sky Is Not Falling Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Gilead Sciences Non-GAAP EPS of $1....
2024-02-06 16:28:59 ET More on Gilead Sciences Gilead Sciences: The Sky Is Not Falling Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Gilead Sciences...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common...
2024-02-06 16:03:41 ET More on Gilead Sciences Gilead Sciences: The Sky Is Not Falling Gilead Sciences, Inc. (GILD) JPMorgan 42nd Annual Healthcare Conference (Transcript) Gilead's Dividend Growth Potential Looks Phenomenal Gilead set to roll out Q4 results p...
Product Sales Excluding Veklury Increased Year-Over-Year by 7% for Full Year 2023 Biktarvy Sales Increased Year-Over-Year by 14% for Full Year 2023 Oncology Sales Increased Year-Over-Year by 37% for Full Year 2023 Gilead Sciences, Inc. (Nasdaq: GILD) announced today its ...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...